XML 36 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 6 Months Ended 191 Months Ended
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2012
Revenues:          
Collaboration and research and development revenue         $ 3,100
Product revenue 120 168 281 360 3,302
Grant revenue 26   26   3,674
Total revenues 146 168 307 360 10,076
Operating expenses:          
Cost of goods sold 89 72 183 178 1,935
Research and development 1,717 1,859 3,064 4,939 188,863
Selling, general and administrative 2,350 2,034 4,346 3,840 93,833
Goodwill and intangible impairment         7,934
Restructuring costs         2,634
Total operating expenses 4,156 3,965 7,593 8,957 295,199
Operating loss (4,010) (3,797) (7,286) (8,597) (285,123)
Other income (expense):          
Costs associated with aborted 2004 IPO         (3,550)
Payment under guarantee         (1,652)
Change in valuation of Economic Rights 146   90   90
Change in valuation of other liabilities measured at fair value 8 125 50 203 6,377
Foreign exchange (losses)/gains 117 (19) 231 (87) (4,098)
Interest income 6 13 12 24 13,737
Interest expense         (4,677)
Other income 29   76   76
Total other income (expense) 306 119 459 140 6,303
Loss before taxes (3,704) (3,678) (6,827) (8,457) (278,820)
Income tax benefit 127 126 295 317 18,739
Net loss (3,577) (3,552) (6,532) (8,140) (260,081)
Dividends on preferred ordinary shares         (38,123)
Deemed dividend on convertible exchangeable preferred shares         (3,515)
Dividend on convertible exchangeable preferred shares (182) (182) (364) (364) (4,021)
Net loss applicable to common shareholders $ (3,759) $ (3,734) $ (6,896) $ (8,504) $ (305,740)
Net loss per share - Basic and diluted (in dollars per share) $ (0.06) $ (0.08) $ (0.12) $ (0.18)  
Weighted average common shares outstanding (in shares) 58,997,078 46,582,915 56,879,349 46,577,577